Numerous investigations have been carried out dealing with the absorption of aureomycin into the blood stream, body fluids, and tissues (1, 2) . However, no determination of the concentration of this antibiotic within the lumen of the intestine has been reported. Likewise, there have been many studies concerning the effect of oral aureomycin on the intestinal bacterial flora, but these have relied upon the examination of stool specimens (3) . It was believed that a determination of the concentration of aureomycin and its bacterial effect in various portions of the intestine would be of value in establishing more accurately the role of this antibiotic in intestinal disease.
For these reasons, it was decided to investigate patients having a cecostomy, a transverse colostomy or a sigmoid colostomy. In this manner, it was possible to correlate oral dosage and intestinal aureomycin levels as well as alterations in the bacterial flora in different portions of the intestinal tract. Similar studies were carried out using stool specimens from a group of hospital patients having no apparent intestinal disease. It was recognized that a comprehensive investigation of intestinal bacteria involving aerobic and anaerobic studies would be an extensive project. A review of the bacteriologic records of the John Gaston Hospital for the five year period from January 1, 1945 to January 1, 1950 disclosed that eight pathogenic organisms were most frequently isolated in cases of peritonitis resulting from perforation of the gastrointestinal tract: Escherichia coli, Streptococcus anaerobius, Bacteroides organisms, Streptococcus Pyogenes, Streptococcus viridans, Strep- tococcus faecalis, Clostridium perfringens, and Aerobacter aerogenes. It was decided to restrict the bacteriologic studies to these eight organisms.
METHODS
Clinical methods. Nine patients having a cecostomy, a transverse colostomy or a sigmoid colostomy were studied. Two of these patients had a cecostomy; three had a transverse colostomy; and four had a sigmoid colostomy. The following procedure was carried out in every case: after obtaining two control specimens, each patient was given 250 mg. of aureomycin orally at 10:00 a.m., 2:00 p.m., 6:00 p.m., and 10:00 p.m. for two days; then, four days after the intestinal or fecal aureomycin had disappeared, this procedure was repeated using 500 mg. instead of 250 mg. of aureomycin; again, after the aureomycin level in the intestine or feces had been nil for four days, 750 mg. of aureomycin were administered four times a day for two days. Medication was followed in every instance with 100 cc. of milk. This particular regimen was adopted because it corresponded to the routine antiamebic treatment employed at the John Gaston Hospital (4). Intestinal specimens were obtained at approximately the same period every 24 hours. One of the two cecostomy patients was unable to remain in the hospital more than 10 days. Therefore, only the 2 gm. regimen was carried out in that case.
In addition to the nine cecostomy and colostomy cases, 20 hospital patients having no apparent gastro-intestinal disease were investigated following the oral administration of aureomycin as described above. Efforts were made to obtain stool specimens daily for five days in each of these cases. Four of these patients were subjected to the 1 gm. regimen, nine to the 2 gm. regimen and seven to the 3 gm. regimen. Attention was especially directed toward the 2 gm. group because it corresponded to our routine anti-amebic therapy (4) .
Assay methods. The method employed for determining aureomycin concentration in feces and intestinal material was suggested by Dornbush (5 three eosin methylene blue plates (Difco). In a similar manner, two drops of the contents of tube 5 were placed on the fourth blood agar plate and the material was then diluted by using the same spreader for the fifth plate. This procedure was also carried out in duplicate. Tube 1 was heated in a water bath at 80°C. for 15 minutes, after which two drops of its contents were placed on the sixth blood agar plate and were subsequently diluted on the seventh plate by using the same glass spreader. One set of blood agar plates and the three eosin methylene blue plates were incubated aerobically at 37°C. for 24 hours. The remaining set of blood agar plates was incubated anaerobically at 370 C. for 48 hours.
The gross appearance of all bacterial colonies was recorded. The first plate was used to determine the number of each type of colony except when it was overgrown. When the first plate could not be employed, the fourth plate was utilized for this purpose; and the number of colonies counted was multiplied by the dilution factor. (Table I) .
With 3 gm. of oral aureomycin daily for two days, persistently higher concentrations were obtained in the intestine and feces than in either of the two preceding groups. Of importance is the fact that significant aureomycin intestinal levels were rapidly attained and were then maintained for two and three days after medication was discontinued. With the exception of the cecostomy case, every patient in this series disclosed intestinal or fecal concentrations of aureomycin reaching 51,-600 to 128,000 mcg. per gmi. of wet material. Since only graded quantitative differences were noted in the results obtained with 1 gm., 2 gm. and 3 gm. of aureomycin, the concentrations demonstrated in the 2 gm. series alone are recorded in Table I. The effect of diarrhea on aureomycin intestinal levels is of obvious practical importance in the treatment of intestinal disease, for example, human amebic dysentery. The rapid decrease in the aureomycin level in patient 3 in the 2 gm. series (Table I) was associated with a painless diarrhea of five to seven liquid stools per day. Additional evidence of the effect of diarrhea in reducing aureomycin intestinal levels was observed in the two cecostomy patients in this series (Table I ). Patient 1 had a persistent, moderately severe diarrhea throughout this investigation; while the second patient noted no side effects. Concentrations obtained in the latter case were four to 12.5 times greater than in the first patient.
Bacteriologic results. To promote cohesion in discussion and representation, the bacteriologic studies involving the various portions of the intestine-cecum, transverse colon and sigmoid colon -were grouped together as intestinal effects. When a reduction of one of the eight bacteria studied was observed from 4 + or 3 + to 1 + or 0 (as previously explained), it was regarded as evidence + Indicates "C" specimens were not obtained. of marked or complete inhibition. If reduction was only in the range of 4 + to 3 + or 3 + to 2 + or 2 + to 1 + or 1 + to 0 or if there was no decrease, it was regarded as slight or no inhibition. This method was employed with both intestinal and fecal specimens.
Even such a minimal amount of oral aureomycin as 1 gm. daily for two days, produced a rapid intestinal effect. Seven of the eight bacteria studied were markedly or completely inhibited in 24 to 48 hours and definite reduction of these organisms persisted for two days after this small amount of medication was discontinued. Only Streptococcus faecalis was not uniformly responsive.
Using 2 and 3 gm. of aureomycin daily for two days, a more rapid and marked reduction of bacteria occurred. While 1 gm. resulted in the complete inhibition of two of the eight bacteria in the intestine in 24 hours, 2 gm. completely inhibited three of these organisms (Table II) , and 3 gm. caused the complete inhibition of six. Similar effects were noted in the fecal specimens. Only Streptococcus faecalis was not uniformly reduced to a significant degree. However, when 3 gm. were administered daily for two days, three of five intestinal cases revealed complete or marked inhibition of this organism, though only one of five of the stool specimens disclosed this degree of reduction. In all cases, the effect on Streptococcus faecalis was brief. A definite inhibition of the other seven bacteria in the intestine and stool was evident for 48 and 72 hours after aureomycin was discontinued.
DISCUSSION
In an effort to evaluate more exactly the role of aureomycin in intestinal disease, material from various portions of the intestine was examined following the administration of therapeutic amounts of this antibiotic. Each specimen was studied to determine the concentration of aureomycin and its effect on eight pathogenic organisms. Using 2 to 3 gm. of oral aureomycin daily, intestinal concentrations of this agent were obtained which reached 51,200 to 128,000 mcg. per gm. of wet material.
These initial aureomycin intestinal levels are quite suggestive as regards the mode of action of this antibiotic in human amebiasis. In 1949, it was demonstrated that aureomycin is amebicidal in vitro (6) . Further evidence indicating a direct effect by this antibiotic on E. histolytica in the test tube was presented by Hewitt and his associates who described the complete destruction of amebae by aureomycin in concentrations of 1,000 mcg. per cc. with only 10 minutes of contact (7) Bacteriologic studies restricted' to eight common pathogenic organisms revealed that 2 to 3 gm. of oral aureomycin daily for two days resulted in a rapid and marked inhibition of seven of these bacteria. This effect persisted for 48 to 72 hours after medication was discontinued. Streptococcus faecalis alone was not uniformly responsive; though when 3 gm. were administered daily, this organism was markedly reduced in more than half of the cases revealing its presence. While the intestinal antibacterial spectrum of aureomycin has been extensively investigated (3), it is believed that information derived from this study of material from different portions of the intestine may be of value in determining more exactly its role in intestinal surgery. In view of the rapid attainment and subsequent maintenance of significant intestinal levels together with its bacterial effects, it appears that aureomycin should be an excellent agent for the preoperative preparation of the intestine. Clinical reports substantiate this view (9, 10) . SUMMARY 1. The oral administration of therapeutic amounts of aureomycin results in the rapid, attainment and rather prolonged maintenance of significant intestinal concentrations of this antibiotic.
2. These first aureomycin intestinal levels indicate that this antibiotic probably exerts its major therapeutic effect in human amebiasis by a direct action on E. histolytica; though there may be a minimal indirect action on amebae resulting from alteration of the intestinal bacterial flora.
3. The studies reported in this paper dealing with the concentration of aureomycin and its bacteriologic action in various portions of the intestine indicate that this antibiotic should be an effective agent for preoperative preparation of the intestine.
